Plus Therapeutics IncNASDAQ:PSTVNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE1.3300
- TODAY'S CHANGE (%)-0.0301 (-2.2131%)
- Bid / Lots1.3400/ 1
- Ask / Lots1.3700/ 1
- Open / Previous Close1.4500 / 1.3601
- Day Range
- 52 Week Range
- Volume18,375
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | PSTV |
|---|---|---|
| 09:32 ET | 10000 | 1.45 |
| 09:39 ET | 1100 | 1.36 |
| 09:42 ET | 300 | 1.36 |
| 10:02 ET | 400 | 1.34 |
| 10:31 ET | 2374 | 1.34 |
| 01:08 ET | 149 | 1.36 |
| 02:23 ET | 750 | 1.33 |
Today
Oct 29, 2024
Plus Therapeutics Showcases Leptomeningeal Metastases Programs at the 2024 SNO Annual Meeting in Houston, Texas, from 7:30AM ET on Tuesday Oct 29, 2024 by Dow Jones
7:30AM ET on Tuesday Oct 29, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Plus Therapeutics Inc | 8.0M | -0.4x | --- |
Kineta Inc | 9.0M | -0.4x | --- |
Stemtech Corp | 3.2M | -0.5x | --- |
InMed Pharmaceuticals Inc | 3.2M | -0.2x | --- |
Evogene Ltd | 10.6M | -0.5x | --- |
COSCIENS Biopharma Inc | 13.8M | -0.4x | --- |
Company Information
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. The Company combines image-guided local beta radiation and targeted drug delivery approaches. The Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). Its radiotherapeutic candidate, rhenium (186Re) obisbemeda, is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC). The Company’s Rhenium (186Re) obisbemeda, a novel injectable radiotherapy designed to deliver targeted, high dose radiation directly into GBM tumors. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers.
Contact Information
- Headquarters
- 4200 Marathon Blvd., Suite 200AUSTIN, TX, United States 78756
- Phone
- 858-458-0900
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Richard Hawkins
- President, Chief Executive Officer, Director
- Marc Hedrick
- Chief Financial Officer
- Andrew Sims
- Vice President - Clinical Operations
- Pius Maliakal
- Independent Director
- Howard Clowes
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $8.0M |
|---|---|
Revenue (TTM) | $5.5M |
Shares Outstanding | 5.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.71 |
EPS | $-3.05 |
Book Value | $-0.30 |
P/E Ratio | -0.4x |
Price/Sales (TTM) | 1.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -256.07% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
